专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20160074811A1 DRAW SOLUTIONS AND METHODS OF TREATING AN AQUEOUS LIQUID 审中-公开
标题翻译：绘制溶液和处理水性液体的方法
公开(公告)号：US20160074811A1
公开(公告)日：2016-03-17
申请号：US14948019
申请日：2015-11-20
申请人： BATTELLE ENERGY ALLIANCE, LLC
发明人： Frederick F. Stewart , Michael T. Benson , Mark L. Stone
IPC分类号： B01D61/00 , C07D251/70 , C02F1/44 , C07F9/6593
CPC分类号： B01D61/005 , B01D61/007 , C02F1/445 , C02F2103/08 , C07D251/54 , C07D251/70 , C07F9/65815
摘要： A method of treating an aqueous liquid. The method comprises providing an aqueous feed liquid comprising water and at least one solute to a first side of a membrane. A draw solution comprising water and a draw solute comprising at least one of a phosphazene compound and a triazine compound is provided to a second side of the membrane. At least a portion of the water of the aqueous feed liquid is osmosed across the membrane and into the draw solution to form a diluted draw solution comprising water and the draw solute. The water of the diluted draw solution is separated from the draw solute of the diluted draw solution to form a purified water product. Draw solutes comprising phosphazene compounds and draw solutes comprising triazine compounds are also disclosed, as are methods of forming the draw solutes.
摘要翻译：一种处理含水液体的方法。该方法包括向膜的第一侧提供包含水和至少一种溶质的含水进料液体。提供包含水和包含磷腈化合物和三嗪化合物中的至少一种的拉伸溶质的拉伸溶液到膜的第二侧。含水进料液体的水的至少一部分渗透穿过膜并进入拉伸溶液以形成包含水和拉伸溶质的稀释的拉伸溶液。将稀释的溶液的水与稀释的溶液的吸附溶液分离，形成净化水产物。还公开了包含磷腈化合物和包含三嗪化合物的溶解溶剂的溶质，以及形成拉伸溶质的方法。

12. 发明申请

US20140288080A1 THERAPEUTIC METHODS AND AGENTS FOR TREATING MYOTONIC DYSTROPHY 有权
标题翻译：用于治疗肌动蛋白的治疗方法和药剂
公开(公告)号：US20140288080A1
公开(公告)日：2014-09-25
申请号：US14297037
申请日：2014-06-05
申请人： Steven C. Zimmerman , Chun-Ho Wong , Paul J. Hergenrother , Jessie Peh
发明人： Steven C. Zimmerman , Chun-Ho Wong , Paul J. Hergenrother , Jessie Peh
IPC分类号： C07D251/70
CPC分类号： C07D251/70 , A61K9/0014 , A61K9/0019 , A61K9/008 , A61K9/06 , A61K9/2054 , A61K9/4858
摘要： The invention provides compounds, compositions and methods for treating myotonic dystrophy. The compounds can selectively bind to CUG repeats in RNA, or to CTG repeats in DNA, and inhibit replication of the nucleic acids.
摘要翻译：本发明提供了用于治疗强直性营养不良的化合物，组合物和方法。这些化合物可以选择性地结合RNA中的CUG重复序列或DNA中的CTG重复序列，并抑制核酸的复制。

13. 发明申请

US20110295001A1 Method for Producing Triazine Carbamates Using Chloroformates 审中-公开
标题翻译：使用氯仿生产三嗪氨基甲酸酯的方法
公开(公告)号：US20110295001A1
公开(公告)日：2011-12-01
申请号：US13133488
申请日：2009-12-07
申请人： René Dicke , Martin Burger , Andreas Endesfelder , Christoph Hahn , Sven Poser , Willy Frank , Manfred Arnold
发明人： René Dicke , Martin Burger , Andreas Endesfelder , Christoph Hahn , Sven Poser , Willy Frank , Manfred Arnold
IPC分类号： C07D251/70 , C07D403/12
CPC分类号： C07D251/70 , C08K5/205 , C08K5/3492 , C09D7/63 , C09D167/00 , C08L2666/36
摘要： The present invention relates to a method for producing triazine carbamates by conversion of at least one triazine with at least one chloroformate in the presence of at least one alkaline or alkaline earth metal compound, wherein the alkaline or alkaline earth metal compound is not present in form of an alcoholate.
摘要翻译：本发明涉及在至少一种碱金属或碱土金属化合物存在下，用至少一种氯甲酸酯转化至少一种三嗪以制备三嗪氨基甲酸酯的方法，其中碱金属或碱土金属化合物不以形式存在的酒精中毒。

14. 发明授权

US08030485B2 Process for the preparation of pulverulent alkoxycarbonylaminotriazine 有权
标题翻译：制备粉状烷氧基羰基氨基三嗪的方法
公开(公告)号：US08030485B2
公开(公告)日：2011-10-04
申请号：US11916747
申请日：2006-05-31
申请人： Joerg Schneider , Guenter Scherr , Rainer Erhardt , Andreas Eichfelder , Martin Reif , Stefan Hirsch , Georg Sieder , Thomas Holtmann , Juergen Ciprian , Hermann Ascherl
发明人： Joerg Schneider , Guenter Scherr , Rainer Erhardt , Andreas Eichfelder , Martin Reif , Stefan Hirsch , Georg Sieder , Thomas Holtmann , Juergen Ciprian , Hermann Ascherl
IPC分类号： C07D251/70 , C07D251/50 , C07D251/48 , C07D251/18
CPC分类号： C07D251/70
摘要： The invention relates to a process for preparing free-flowing, pulverulent alkoxycarbonylaminotriazine from an alkanolic reaction mixture which is obtained in the preparation of alkoxycarbonylaminotriazines and comprises at least one alkoxycarbonylaminotriazine, at least one cyclic and/or acyclic carbonic ester, at least one C1-C13-alkanol which optionally comprises one or two oxygen atoms in the form of ether bonds and is optionally substituted by C1-C4-alkyl and/or hydroxyl, and also at least one alkali metal or alkaline earth metal alkoxide, with or without melamine and with or without catalyst, by atomizing and drying the reaction mixture in a spray drier.
摘要翻译：本发明涉及一种从烷醇反应混合物中制备自由流动的粉末状烷氧基羰基氨基三嗪的方法，其在制备烷氧基羰基氨基三嗪时得到，并且包含至少一种烷氧基羰基氨基三嗪，至少一种环状和/或无环碳酸酯，至少一个C1- 任选地包含一个或两个醚键形式的氧原子并且任选被C 1 -C 4 - 烷基和/或羟基取代的C 13 - 链烷醇，以及至少一种具有或不具有三聚氰胺的碱金属或碱土金属醇盐，以及具有或不具有催化剂，通过在喷雾干燥器中雾化和干燥反应混合物。

15. 发明申请

US20100298200A1 Compounds and assays for controlling Wnt activity 有权
标题翻译：用于控制Wnt活性的化合物和测定法
公开(公告)号：US20100298200A1
公开(公告)日：2010-11-25
申请号：US12454765
申请日：2009-05-22
申请人： Dakai Liu , Xiaofeng Li , Richard Jin , Yuaxin Liang , Wei Cheng , Riddhi Bhattacharyya , Guangrong Zhang
发明人： Dakai Liu , Xiaofeng Li , Richard Jin , Yuaxin Liang , Wei Cheng , Riddhi Bhattacharyya , Guangrong Zhang
IPC分类号： A61K38/02 , C07D265/38 , C07C309/53 , C07C235/56 , C07D251/70 , C07C229/66 , A61K31/538 , A61K31/196 , A61K31/185 , A61K31/277 , A61K31/53 , A61K31/245 , A61K31/366 , A61K31/12 , A61K31/165 , A61K31/167 , A61K31/505 , A61K31/122 , A61K31/235 , A61K31/05 , A61K31/365 , A61K31/343 , A61P31/12 , A61P25/00 , A61P19/00 , A61P35/00 , A61P3/08 , A61P3/06 , G01N33/00 , C12Q1/02 , C12Q1/68 , G01N33/53 , G01N33/542 , C40B30/04 , C40B30/02 , C12N5/10 , C12Q1/66
CPC分类号： G01N33/6845 , A61K31/536 , A61K31/538 , C07D265/28 , C07D265/34 , C07D265/38 , C40B30/02 , G01N2800/36
摘要： The present invention relates to the field of therapeutic methods to screen for compounds on the basis of their ability to influence Wnt activity. The screening process is applied to both a physical library of a series of compounds and a virtual library of compounds that affect Wnt activity. In one aspect, the virtual screening process could be carried out where a permutational library of small peptides is substituted for the small organic molecules. The inventive methods may be used to empirically test for effects on Wnt activity and may also be applied to any pair of proteins involved in protein-protein interactions.
摘要翻译：本发明涉及根据其影响Wnt活性的能力筛选化合物的治疗方法领域。筛选过程适用于一系列化合物的物理文库和影响Wnt活性的化合物的虚拟文库。在一个方面，虚拟筛选过程可以在小肽的置换文库替代小有机分子的地方进行。本发明的方法可用于经验性地测试对Wnt活性的影响，并且还可以应用于涉及蛋白质 - 蛋白质相互作用的任何一对蛋白质。

16. 发明授权

US07517474B2 Carbamate-functional triazine derivatives 有权
标题翻译：氨基甲酸酯官能的三嗪衍生物
公开(公告)号：US07517474B2
公开(公告)日：2009-04-14
申请号：US11547476
申请日：2005-04-08
申请人： Eva Wagner , Reinhold Schwalm , Joerg Schneider , Rainer Erhardt , Carl Jokisch , Heinz-Peter Rink
发明人： Eva Wagner , Reinhold Schwalm , Joerg Schneider , Rainer Erhardt , Carl Jokisch , Heinz-Peter Rink
IPC分类号： C07D251/54 , C07D251/70 , C09D175/04
CPC分类号： C07D251/54
摘要： New triazine derivatives containing carbamate groups, processes for preparing them, and their use.
摘要翻译：含有氨基甲酸酯基团的新型三嗪衍生物，其制备方法及其用途。

17. 发明授权

US07375222B2 2,4,6-Triamino-1,3,5-triazine derivative 有权
标题翻译： 2,4,6-三氨基-1,3,5-三嗪衍生物
公开(公告)号：US07375222B2
公开(公告)日：2008-05-20
申请号：US10503494
申请日：2003-02-03
申请人： Hideki Kubota , Takeshi Suzuki , Masanori Miura , Eiichi Nakai , Kiyoshi Yahiro , Akira Miyake , Shinobu Mochizuki , Kazuhiro Nakatou
发明人： Hideki Kubota , Takeshi Suzuki , Masanori Miura , Eiichi Nakai , Kiyoshi Yahiro , Akira Miyake , Shinobu Mochizuki , Kazuhiro Nakatou
IPC分类号： C07D251/70 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , A61K31/53 , A61P25/28
CPC分类号： C07D471/04 , A61K31/53 , C07D251/70 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D453/02 , C07D491/04
摘要： This invention relates to an anti-dementia agent which uses a BEC 1 potassium channel inhibitor as the active ingredient.It was proved that the BEC 1 potassium channel inhibitor has an action to improve learning disorder and is useful as a preventive or therapeutic agent for diseases, preferably dementia, in which the BEC 1 potassium channel is considered to be concerned.Illustratively, it was confirmed by an in vivo test that the BEC 1 potassium channel inhibitor has an action to improve learning disorder.Also, it was found that a compound having 2,4,6-triamino-1,3,5-triazine has a BEC 1 potassium channel inhibitory action.
摘要翻译：本发明涉及使用BEC 1钾通道抑制剂作为活性成分的抗痴呆药。证明BEC 1钾通道抑制剂具有改善学习障碍的作用，可用作预防或治疗BEC 1钾通道所涉及的疾病，优选痴呆症。说明性地，通过体内试验证实BEC 1钾通道抑制剂具有改善学习障碍的作用。此外，发现具有2,4,6-三氨基-1,3,5-三嗪的化合物具有BEC 1钾通道抑制作用。

18. 发明授权

US07332488B2 Methods and compositions of novel triazine compounds 失效
公开(公告)号：US07332488B2
公开(公告)日：2008-02-19
申请号：US11511129
申请日：2006-08-28
申请人： Richard T. Timmer , Christopher W. Alexander , Sivaram Pillarisetti , Uday Saxena , Koteswar Rao Yeleswarapu , Manojit Pal , Jangalgar Tirupathy Reddy , Velagala Venkata Rama Murali Krishna Reddy , Sesha Sridevi Alluri , Potlapally Rajender Kumar , Gaddam Om Reddy
发明人： Richard T. Timmer , Christopher W. Alexander , Sivaram Pillarisetti , Uday Saxena , Koteswar Rao Yeleswarapu , Manojit Pal , Jangalgar Tirupathy Reddy , Velagala Venkata Rama Murali Krishna Reddy , Sesha Sridevi Alluri , Potlapally Rajender Kumar , Gaddam Om Reddy
IPC分类号： C07D251/52 , C07D251/70 , C07D401/12 , C07D403/12 , A61K31/53 , A61P35/00
CPC分类号： A61K31/53 , C04B35/632 , C07D251/30 , C07D251/44 , C07D251/46 , C07D251/48 , C07D251/50 , C07D251/52 , C07D251/54 , C07D251/66 , C07D251/70 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/12 , C07D417/14 , C07D453/02 , C07D471/04 , C07D487/04 , C07F9/6521 , C07F9/65583
摘要： The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

19. 发明授权

US07189720B2 Selective NPY (Y5) antagonists 失效
标题翻译：选择性NPY（Y5）拮抗剂
公开(公告)号：US07189720B2
公开(公告)日：2007-03-13
申请号：US11099960
申请日：2005-04-06
申请人： Mohammad R. Marzabadi , Stewart A. Noble , Mahesh N. Desai
发明人： Mohammad R. Marzabadi , Stewart A. Noble , Mahesh N. Desai
IPC分类号： C07D251/50 , C07D251/70 , A61K31/53 , A61P3/04
CPC分类号： C07D401/12 , C07D251/70 , C07D277/28 , C07D277/42 , C07D403/12 , C07D409/12 , C07D413/12 , C07D417/04 , C07D417/12 , C07D417/14 , C07D513/04
摘要： This invention is directed to triazine derivatives, bicyclic compounds and tricyclic compounds which are selective antagonists for a NPY (Y5) receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of this invention and a pharmaceutically acceptable carrier. This invention provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The invention further provides the use of a compound of the invention for the preparation of a pharmaceutical composition for treating an abnormality, wherein the abnormality is alleviated by decreasing the activity of a human Y5 receptor.
摘要翻译：本发明涉及作为NPY（Y5）受体的选择性拮抗剂的三嗪衍生物，双环化合物和三环化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物和药学上可接受的载体组合而制备的药物组合物。本发明提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。本发明还提供了本发明化合物在制备用于治疗异常的药物组合物中的用途，其中通过降低人Y5受体的活性来减轻异常。

20. 发明授权

US07169784B2 Medical devices employing triazine compounds and compositions thereof 失效
公开(公告)号：US07169784B2
公开(公告)日：2007-01-30
申请号：US10951316
申请日：2004-09-27
申请人： Richard T. Timmer , Christopher W. Alexander , Sivaram Pillarisetti , Uday Saxena , Koteswar Rao Yeleswarapu , Manojit Pal , Jangalger Tirupathy Reddy , Velagala Venkata Rama Murali Krishna Reddy , Bhatlapenumarthy Sesha Sridevi Alluri , Potlapally Rajender Kumar , Gaddam Om Reddy
发明人： Richard T. Timmer , Christopher W. Alexander , Sivaram Pillarisetti , Uday Saxena , Koteswar Rao Yeleswarapu , Manojit Pal , Jangalger Tirupathy Reddy , Velagala Venkata Rama Murali Krishna Reddy , Bhatlapenumarthy Sesha Sridevi Alluri , Potlapally Rajender Kumar , Gaddam Om Reddy
IPC分类号： A61M31/00 , A61M2/86 , C07D251/70 , C07D251/52 , C07D251/30
CPC分类号： A61K31/53 , C04B35/632 , C07D251/30 , C07D251/44 , C07D251/46 , C07D251/48 , C07D251/50 , C07D251/52 , C07D251/66 , C07D251/70 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/12 , C07D417/14 , C07D453/02 , C07D487/04 , C07F9/6521 , C07F9/65583
摘要： The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式